Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Unconventional myosin-V is a class of actin-based motor proteins that play a vital role in the intracellular transport of organelles and vesicles. In humans, the family comprises three isoforms (Va, Vb, and Vc), with Myosin Va being the most extensively studied for its role in transporting melanosomes in skin cells and synaptic vesicles in the brain (1). Mutations in the MYO5A gene are the primary cause of Griscelli syndrome type 1, a rare autosomal recessive disorder characterized by pigmentary dilution and severe neurological impairment (2). Myosin Vb is critical for membrane recycling in epithelial cells, and its dysfunction leads to microvillus inclusion disease, a life-threatening diarrheal condition (3). From a therapeutic perspective, Myosin V is an emerging target in oncology, as it facilitates the transport of vesicles containing pro-migratory factors that drive cancer cell invasion and metastasis (4). While small molecule inhibitors like pentachloropseudilin are used in research to probe its ATPase cycle, there are currently no FDA-approved drugs specifically targeting Myosin V, though it remains a significant focus for treating pigmentary and neurodegenerative conditions (5). Citations: (1) UniProt Consortium. "Unconventional myosin-Va (P42108)." UniProtKB. (2) Pastural, E., et al. (1997). "Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene." Nature Genetics. (3) Müller, T., et al. (2008). "MYO5B mutations cause microvillus inclusion disease and disrupt epithelial cell polarity." Nature Genetics. (4) Fedoryshchak, R. O., et al. (2020). "Small molecule inhibitors of unconventional myosins." ACS Chemical Biology. (5) Hammer, J. A., & Sellers, J. R. (2012). "Walking to work: roles for class V myosins as cargo transporters." Nature Reviews Molecular Cell Biology.
Small molecule inhibitors typically target the ATPase activity of the motor domain or interfere with the actin-binding cycle, thereby preventing the translocation of cargo along actin filaments.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Unconventional myosin-Va (MYO5A) (MYO5A).